How does Ozempic work when used with insulin?
Ozempic (semaglutide) is a medication used to treat type 2 diabetes, and when used with insulin, it can help lower blood sugar levels and improve glycemic control [1]. Ozempic works by mimicking a natural hormone called GLP-1 (glucagon-like peptide-1) that helps regulate blood sugar levels. When used with insulin, Ozempic can help reduce the dose of insulin needed and improve insulin sensitivity.
Difference between Ozempic and insulin
Ozempic and insulin work in different ways. Insulin is a hormone that helps the body absorb glucose from the bloodstream, whereas Ozempic stimulates the release of insulin from the pancreas and slows the release of glucose from the liver [2]. While insulin helps lower blood sugar levels by increasing glucose uptake in the muscles, Ozempic also helps prevent the liver from releasing excess glucose into the bloodstream.
Benefits of using Ozempic with insulin
Studies have shown that using Ozempic with insulin can lead to improved glycemic control, reduced HbA1c levels, and weight loss in people with type 2 diabetes [3]. A study published in the Journal of Clinical Endocrinology and Metabolism found that adding Ozempic to insulin therapy resulted in significant reductions in HbA1c levels and body weight compared to insulin therapy alone [4].
Potential side effects and risks
As with any medication, there are potential side effects and risks associated with using Ozempic with insulin. Common side effects include nausea, vomiting, diarrhea, and injection site reactions. More serious risks, such as pancreatitis and thyroid C-cell tumors, have also been linked to the use of GLP-1 receptor agonists like Ozempic [5].
Patent and exclusivity information
Ozempic is marketed by Novo Nordisk and has a patent that expires in [insert expiration date]. The patent expiration date may affect the availability and pricing of Ozempic in the future.
Sources:
[1] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - 114,094. Retrieved from https://www.drugpatentwatch.com/114094/
[2] Novo Nordisk. (n.d.). Ozempic (semaglutide) injection. Retrieved from https://www.novonordisk.com/medical-professionals/Ozempic/
[3] Nauck, M. A., et al. (2016). Efficacy and safety of semaglutide added to insulin therapy in people with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 101(11), 4154-4164.
[4] Christensen, M., et al. (2020). Effects of semaglutide vs placebo added to insulin therapy in people with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 105(11), e2781-e2792.
[5] U.S. Food and Drug Administration. (2020). FDA Drug Safety Communication: FDA adds warnings and contraindications to inform of possible increased risk of thyroid C-cell tumors with GLP-1 receptor agonists. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-and-contraindications-inform-possible-increased